Sebastiano Virgadamo, DO
Interventional Cardiology · Spartanburg, SCNPI 1336439074
Payments from drug & device makers
Across 525 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$5K
- Abbott$1K
- Medtronic$961
- Stryker$780
- Boston Scientific$632
- Novartis$632
- plus $4K from 29 others
What the payments were for
- Travel & lodging$1,82713%
- Food & beverage$11,80686%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 123 | $5,159 |
| Abbott | 91 | $1,466 |
| Medtronic(2 entities) | 21 | $961 |
| Stryker | 40 | $780 |
| Boston Scientific | 20 | $632 |
| Novartis | 36 | $632 |
| Abiomed | 24 | $588 |
| AstraZeneca | 17 | $372 |
| E.r. Squibb & Sons, L.L.C. | 16 | $311 |
| Endologix LLC | 1 | $307 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $293 |
| Pfizer | 19 | $292 |
| Cardiovascular Systems Inc. | 11 | $286 |
| Atricure, Inc. | 9 | $197 |
| Johnson & Johnson | 11 | $197 |
| Heartflow, Inc. | 4 | $170 |
| Cvrx, Inc. | 2 | $144 |
| Amgen | 9 | $141 |
| Merck | 7 | $139 |
| Alnylam Pharmaceuticals Inc. | 4 | $86 |
| Shockwave Medical, Inc | 3 | $74 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $55 |
| Chiesi USA, Inc. | 3 | $53 |
| Recor Medical Inc | 2 | $49 |
| Kestra Medical Technology Services, Inc. | 3 | $49 |
| Edwards Lifesciences | 2 | $49 |
| Boehringer Ingelheim | 2 | $48 |
| Cardiva Medical, Inc. | 1 | $22 |
| Bayer | 1 | $17 |
| Surmodics, Inc. | 2 | $16 |
| Cagent Vascular Inc | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| Terumo Medical Corporation | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Altathera Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$3,570
- CT THROMBECTOMY SYSTEM KIT$2,874
- Abre$448
- ENDOCROSS Device$307
- Torus Stent Graft System$307
- Dragonfly OCT$198
- WATCHMAN FLX$149
- AVVIGO Guidance System$144
- Barostim Neo System$121
How this compares
$13,655 in reported general payments places this provider in the 55th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 439 | $445,607 |
| EntrestoSacubitril/Valsartan | 135 | $167,279 |
| XareltoRivaroxaban | 55 | $52,437 |
| FarxigaDapagliflozin Propanediol | 42 | $46,747 |
| Repatha SureclickEvolocumab | 41 | $34,442 |
| BrilintaTicagrelor | 50 | $28,917 |
| Atorvastatin Calcium | 496 | $5,255 |
| Rosuvastatin Calcium | 190 | $3,308 |
| Metoprolol Succinate | 284 | $3,228 |
| Metoprolol Tartrate | 507 | $2,479 |
| Amlodipine Besylate | 392 | $2,199 |
| Carvedilol | 320 | $2,110 |
| Lisinopril | 252 | $2,025 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 210 | $2,001 |
| Losartan Potassium | 234 | $1,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $292 | $445,607439 claims |
| NovartisEntresto | $632 | $167,279135 claims |
| AstraZenecaFarxiga, Brilinta | $372 | $75,66492 claims |
| Johnson & JohnsonXarelto | $197 | $52,43755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Spartanburg
- Brian BrownSpartanburg$477K
- Aaron GopalSpartanburg$34K
- Mathew KalapurakalSpartanburg$14K
- Daniel SteinbergCharleston$1.1M
- Nicholas AmorosoPawleys Island$1.1M
- Robert LeonardiWest Columbia$881K
- Lars RunquistCharleston$861K
- Kurt BarringhausColumbia$536K
- Josh DollGreenville$429K
- Thomas TodoranPawleys Island$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.